Camber Capital Management LP Bicycle Therapeutics PLC Transaction History
Camber Capital Management LP
- $3.15 Billion
- Q3 2024
A detailed history of Camber Capital Management LP transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Camber Capital Management LP holds 915,000 shares of BCYC stock, worth $13.8 Million. This represents 0.66% of its overall portfolio holdings.
Number of Shares
915,000
Previous 915,000
-0.0%
Holding current value
$13.8 Million
Previous $18.5 Million
11.8%
% of portfolio
0.66%
Previous 0.51%
Shares
3 transactions
Others Institutions Holding BCYC
# of Institutions
112Shares Held
41.2MCall Options Held
39.6KPut Options Held
24.6K-
Baker Bros. Advisors LP New York, NY9.4MShares$142 Million2.28% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.55MShares$53.6 Million2.97% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.34MShares$35.4 Million9.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$34.1 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY1.96MShares$29.6 Million0.74% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $449M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...